Please assess the completion status of the following clinical trial:

Trial Title: Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with SCI (\>6months after spinal cord injury) at the T6 level/above~Exclusion Criteria:~* Pregnant and lactating females~* Heart failure, vascular disease, or stroke~* Advanced chronic obstructive pulmonary disease (COPD), liver disease, and chronic kidney disease~* BMI \>38 kg/m2~* Mechanical ventilation dependence~* The following medications are not allowed (potential interaction with buspirone or inhibition of the CYP3A4 system):~  * cimetidine~ * ketoconazole~ * ritonavir~ * itraconazole~ * erythromycin~ * diltiazem~ * verapamil~ * Monoamine oxidase (MAO) inhibitors \[such as Marplan, Nardil, Parmate, Emsam\]~ * Other prohibited concomitant medications include haloperidol, trazodone, or triazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Buspirone (Type: ACTIVE_COMPARATOR): This drug will be taken for two week period
- Trazodone (Type: ACTIVE_COMPARATOR): This drug will be taken for two week period
- Placebo (Type: PLACEBO_COMPARATOR): A placebo pill will be taken at bed time for two week period

Based on this trial design, predict the completion outcome and termination type (if applicable).